Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Veterinary parvovirus antibody

A canine parvovirus, feline parvovirus technology, applied in the direction of antibodies, antiviral agents, antibody medical components, etc.

Pending Publication Date: 2022-05-10
KINDRED BIOSCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] There are currently no USDA or FDA-approved therapies specifically for CPV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Veterinary parvovirus antibody
  • Veterinary parvovirus antibody
  • Veterinary parvovirus antibody

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0199] Pharmaceutical compositions can be stored in lyophilized form. Thus, in some embodiments, the method of preparation includes a lyophilization step. The lyophilized composition can then be reconstituted, usually as an aqueous composition suitable for parenteral administration, prior to administration to dogs, cats or horses. In other embodiments, especially where the antibody is highly stable to thermal and oxidative denaturation, the pharmaceutical composition may be stored as a liquid, i.e. as an aqueous composition, which may be administered directly or with appropriate dilution for dogs, cats or horses. Lyophilized compositions can be reconstituted with sterile water for injection (WFI). Antimicrobial agents (eg, bacteriostats such as benzyl alcohol) may be included. Accordingly, the present invention provides pharmaceutical compositions in solid or liquid form.

[0200] When administered, the pH of the pharmaceutical composition may be in the range of about pH 5...

Embodiment 1

[0224] Preparation of chimeric canine antibodies Mab A and Mab B

[0225] Structures of canine and feline parvovirus complexed with antibody fragments from eight different neutralizing monoclonal antibodies are reported in Hafenstein S. et al., J Virol. 2009 Jun, 83(11):5556-66 analyze. Incomplete amino acid sequence information is provided for rat Mab E and Mab F Fab fragments that exhibit neutralization of canine parvovirus in in vitro assays. The partial amino acid sequences of the variable heavy chain and variable light chain of Mab E are SEQ ID NO. 81 and 82, respectively. The partial amino acid sequences of the variable heavy chain and variable light chain of Mab F are SEQ ID NO. 83 and 84, respectively.

[0226] Three-dimensional protein structure analysis was performed to construct the redesigned first framework regions of the heavy and light chains of Mab E and Mab F. The amino acid sequences of the heavy and light chains of the redesigned monoclonal antibodies des...

Embodiment 2

[0230] Chimeric canine antibody Mab A and Mab B activities

[0231] Both purified chimeric canine Mab A and Mab B (formulated at 200 μg / mL in PBS (pH 7.2)) were used to assess anti-canine parvovirus activity using a hemagglutination inhibition (HI) assay. Assays were performed at the Companion Animal Vaccine and Immunodiagnostic Services Laboratory at the University of Wisconsin substantially as described by Carmichael et al., Am J of VetRes. 1980 May, 41(5):784-91. Serial dilutions of chimeric canine Mab A and chimeric canine Mab B samples incubated with CPV were prepared. Then add porcine red blood cells. Canine parvovirus-induced agglutination of porcine erythrocytes. Both chimeric canine Mab A and chimeric canine Mab B prevented agglutination. Both antibodies yielded a CPV-2b HI of 40960, while an irrelevant canine IgG yielded a HI of <20. Most vaccinated dogs are thought to have an antibody HI of about 1280.

[0232] In addition, the activity of antibodies to prevent...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Various embodiments are provided that relate to parvovirus antibodies, including canized antibodies, felized antibodies, and chimeric antibodies, that bind to canine and / or feline parvoviruses, for example, with improved expression characteristics. In various embodiments, the parvovirus antibodies have ADCC, ADCP, and / or CDC effector functions. In various embodiments, such monoclonal parvovirus antibodies can be used in methods of preventing and / or treating parvovirus infection in subjects, such as dogs and cats. For example, the provided parvovirus antibodies can be used to provide passive immunity against canine or feline parvovirus infection.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 62 / 880,650, filed July 30, 2019, U.S. Provisional Application No. 62 / 968,970, filed January 31, 2020, and U.S. Provisional Application No. 63 / 030,123, filed May 26, 2020 , each of which is incorporated herein by reference in its entirety for any purpose. technical field [0003] The present invention relates to isolated canine parvovirus antibodies, e.g., having improved recombinant production and neutralizing binding to canine parvovirus and / or feline parvovirus; and methods of using said antibodies, e.g., for use in companion animals such as dogs and cats) to provide passive immunization against parvovirus infection in dogs or felines and / or to treat parvovirus infections. Background technique [0004] Canine parvovirus (CPV) is the most important enterovirus infecting dogs worldwide 1 . CPV virions are non-enveloped DNA viruses. There are several variants ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/08A61K39/23
CPCC07K16/081C07K2317/24C07K2317/76C07K2317/94A61K2039/505C07K2317/92A61P31/20A61K39/42C07K2317/515C07K2317/52
Inventor H·詹L·阮E·拉特克利夫R·陈S·J·李
Owner KINDRED BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com